Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CV Therapeutics’ Ranexa Grows In Fourth Quarter; Partner Talks Continue

This article was originally published in The Pink Sheet Daily

Executive Summary

New heart indication, diabetes could be next, as pendulum swings to company’s favor, analyst tells “The Pink Sheet” DAILY.

You may also be interested in...



CVT gets $175M For Half Of Lexiscan Royalties

Cash adds flexibility to Ranexa partner talks, company tells “The Pink Sheet” DAILY.

CVT gets $175M For Half Of Lexiscan Royalties

Cash adds flexibility to Ranexa partner talks, company tells “The Pink Sheet” DAILY.

CV Therapeutics Seeks Ranexa Labeling Changes Based on MERLIN Study

sNDA includes new analysis of MERLIN-TIMI 36 data, which should eliminate safety concerns around QTc prolongation, clinical researchers report at the European Society of Cardiology.

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel